End-of-day quote
Other stock markets
|
||
- USD | - |
04-22 | 3Sbio Inc. Announces Management Changes | CI |
04-15 | 3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia | MT |
Sales 2024 * | 8.66B 1.2B 1.63B | Sales 2025 * | 9.46B 1.31B 1.78B | Capitalization | 14.53B 2.01B 2.74B |
---|---|---|---|---|---|
Net income 2024 * | 1.94B 268M 365M | Net income 2025 * | 2.14B 296M 403M | EV / Sales 2024 * | 1.77 x |
Net Debt 2024 * | 830M 115M 156M | Net cash position 2025 * | 999M 138M 188M | EV / Sales 2025 * | 1.43 x |
P/E ratio 2024 * |
8.01
x | P/E ratio 2025 * |
7.28
x | Employees | - |
Yield 2024 * |
3.57% | Yield 2025 * |
4.16% | Free-Float | 73.92% |
Managers | Title | Age | Since |
---|---|---|---|
Jing Lou
CEO | Chief Executive Officer | 61 | 92-12-31 |
Xiang He
DFI | Director of Finance/CFO | - | 23-07-02 |
Dong Mei Su
BRD | Director/Board Member | 54 | 12-06-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bin Huang
BRD | Director/Board Member | 63 | 92-12-31 |
Jing Lou
CEO | Chief Executive Officer | 61 | 92-12-31 |
Dong Mei Su
BRD | Director/Board Member | 54 | 12-06-10 |
1st Jan change | Capi. | |
---|---|---|
-1.26% | 89.46B | |
+2.76% | 40.74B | |
-9.06% | 33.03B | |
+55.32% | 24.68B | |
-16.61% | 15.12B | |
-9.14% | 12.81B | |
-12.11% | 11.79B | |
-43.61% | 11.64B | |
+7.79% | 8.9B |